Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02780479 · ClinicalTrials.gov registry record · Phase 4

Steroids in Children Hospitalized With Asthma

A Phase 4 study, sponsored by University of Florida.

Terminated
Registry status
Phase 4
Development phase
6
Enrollment target

NCT02780479: Clinical Trial Phase 4 study, sponsored by University of Florida.

NCT02780479 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02780479, a Phase 4 study, was terminated before completion, sponsored by University of Florida.

TERMINATED
Registry status
Phase 4
Development phase
6 participants
Enrollment target

Study Summary

Asthma is the most common chronic disease of children. A short (3-5 day) course of a short-acting steroid such as Prednisone or Prednisolone has long been the standard of care for asthma exacerbation. Dexamethasone efficacy in asthma exacerbation has been studied in the outpatient setting and was found to be as effective as Prednisone. Dexamethasone has the advantage of shorter course, more compliance, and more tolerable. This has led many emergency departments to provide a 1-2 dose course of Dexamethasone on discharge. Thus, many inpatients have received a first dose of Dexamethasone prior to reaching the inpatient unit, leading to confusion about the best plan for these patients. Many hospitalist pediatricians continue to give a 5-day total course with Prednisone, but some patients have begun to receive a second dose of Dexamethasone 24 hours after the first dose. To our knowledge, no studies have been done to compare the efficacy of these two protocols in pediatric patients requiring hospitalization. The hypothesis is that a second dose of Dexamethasone is as effective as four additional days of Prednisone in hospitalized children with asthma exacerbation. This is an open label, randomized control study comparing these treatments in children age 2-18 hospitalized with asthma exacerbation who have received a first dose of Dexamethasone.

Primary Outcome

Proportion of patients who have returned to normal activity

Interventions

  • DRUG Dexamethasone
  • DRUG Prednisone

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2017-03-20
Est. Completion 2017-08-29
Phase Phase 4
University of Florida

1,106 total trials

Why NCT02780479 stopped before completion

NCT02780479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.

NCT02780479 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02780479 about?

NCT02780479 is a clinical study titled "Steroids in Children Hospitalized With Asthma". Asthma is the most common chronic disease of children. A short (3-5 day) course of a short-acting steroid such as Prednisone or Prednisolone has long been the standard of care for asthma exacerbation. Dexamethasone efficacy in asthma exacerbation has been studied in the outpatient setting and was fo...

What is the current status of trial NCT02780479?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2017-03-20. Estimated completion is 2017-08-29.

What interventions are being tested in trial NCT02780479?

The interventions under investigation include: Dexamethasone (DRUG), Prednisone (DRUG).

Who is sponsoring clinical trial NCT02780479?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02780479's enrollment target sits among peer trials

6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02780479, the US trial registry maintained by the National Library of Medicine. NCT02780479 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.